 | • レポートコード：MRC23Q36341 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のS1P受容体調節薬市場について調査・分析し、世界のS1P受容体調節薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（フィンゴリモド、オザニモド、シポニモド、その他）、用途別セグメント分析（病院薬局、小売店、オンライン薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis International AG、Bristol Myers Squibb、Pfizer Inc.、Sanofi SA、Merck & Co., Inc.、Biogen Inc.、Roche Holding AGなどが含まれています。世界のS1P受容体調節薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、S1P受容体調節薬市場規模を推定する際に考慮しました。本レポートは、S1P受容体調節薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、S1P受容体調節薬に関するビジネス上の意思決定に役立てることを目的としています。 ・S1P受容体調節薬市場の概要 - S1P受容体調節薬のタイプ別セグメント - 世界のS1P受容体調節薬市場規模：タイプ別分析（フィンゴリモド、オザニモド、シポニモド、その他） - S1P受容体調節薬の用途別セグメント - 世界のS1P受容体調節薬市場規模：用途別分析（病院薬局、小売店、オンライン薬局、その他） - 世界のS1P受容体調節薬市場規模予測（2018年-2029年） ・S1P受容体調節薬市場の成長トレンド - S1P受容体調節薬の地域別市場規模（2018年-2029年） - S1P受容体調節薬市場ダイナミクス - S1P受容体調節薬の業界動向 - S1P受容体調節薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：フィンゴリモド、オザニモド、シポニモド、その他 - 世界のS1P受容体調節薬のタイプ別市場規模（2018年-2023年） - 世界のS1P受容体調節薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、小売店、オンライン薬局、その他 - 世界のS1P受容体調節薬の用途別市場規模（2018年-2023年） - 世界のS1P受容体調節薬の用途別市場規模（2024年-2029年） ・S1P受容体調節薬の地域別市場規模 - 北米のS1P受容体調節薬市場規模（2018年-2029年） - アメリカのS1P受容体調節薬市場規模（2018年-2029年） - ヨーロッパのS1P受容体調節薬市場規模（2018年-2029年） - アジア太平洋のS1P受容体調節薬市場規模（2018年-2029年） - 中国のS1P受容体調節薬市場規模（2018年-2029年） - 日本のS1P受容体調節薬市場規模（2018年-2029年） - 韓国のS1P受容体調節薬市場規模（2018年-2029年） - インドのS1P受容体調節薬市場規模（2018年-2029年） - オーストラリアのS1P受容体調節薬市場規模（2018年-2029年） - 中南米のS1P受容体調節薬市場規模（2018年-2029年） - 中東・アフリカのS1P受容体調節薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Novartis International AG、Bristol Myers Squibb、Pfizer Inc.、Sanofi SA、Merck & Co., Inc.、Biogen Inc.、Roche Holding AG ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global S1P Receptor Modulator Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for S1P Receptor Modulator Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for S1P Receptor Modulator Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for S1P Receptor Modulator Drugs in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of S1P Receptor Modulator Drugs include Novartis International AG, Bristol Myers Squibb, Pfizer Inc., Sanofi SA, Merck & Co., Inc., Biogen Inc. and Roche Holding AG, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for S1P Receptor Modulator Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding S1P Receptor Modulator Drugs.
The S1P Receptor Modulator Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global S1P Receptor Modulator Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the S1P Receptor Modulator Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis International AG
Bristol Myers Squibb
Pfizer Inc.
Sanofi SA
Merck & Co., Inc.
Biogen Inc.
Roche Holding AG
Segment by Type
Fingolimod
Ozanimod
Siponimod
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of S1P Receptor Modulator Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global S1P Receptor Modulator Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Fingolimod
1.2.3 Ozanimod
1.2.4 Siponimod
1.2.5 Others
1.3 Market by Application
1.3.1 Global S1P Receptor Modulator Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global S1P Receptor Modulator Drugs Market Perspective (2018-2029)
2.2 S1P Receptor Modulator Drugs Growth Trends by Region
2.2.1 Global S1P Receptor Modulator Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 S1P Receptor Modulator Drugs Historic Market Size by Region (2018-2023)
2.2.3 S1P Receptor Modulator Drugs Forecasted Market Size by Region (2024-2029)
2.3 S1P Receptor Modulator Drugs Market Dynamics
2.3.1 S1P Receptor Modulator Drugs Industry Trends
2.3.2 S1P Receptor Modulator Drugs Market Drivers
2.3.3 S1P Receptor Modulator Drugs Market Challenges
2.3.4 S1P Receptor Modulator Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top S1P Receptor Modulator Drugs Players by Revenue
3.1.1 Global Top S1P Receptor Modulator Drugs Players by Revenue (2018-2023)
3.1.2 Global S1P Receptor Modulator Drugs Revenue Market Share by Players (2018-2023)
3.2 Global S1P Receptor Modulator Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by S1P Receptor Modulator Drugs Revenue
3.4 Global S1P Receptor Modulator Drugs Market Concentration Ratio
3.4.1 Global S1P Receptor Modulator Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by S1P Receptor Modulator Drugs Revenue in 2022
3.5 S1P Receptor Modulator Drugs Key Players Head office and Area Served
3.6 Key Players S1P Receptor Modulator Drugs Product Solution and Service
3.7 Date of Enter into S1P Receptor Modulator Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 S1P Receptor Modulator Drugs Breakdown Data by Type
4.1 Global S1P Receptor Modulator Drugs Historic Market Size by Type (2018-2023)
4.2 Global S1P Receptor Modulator Drugs Forecasted Market Size by Type (2024-2029)
5 S1P Receptor Modulator Drugs Breakdown Data by Application
5.1 Global S1P Receptor Modulator Drugs Historic Market Size by Application (2018-2023)
5.2 Global S1P Receptor Modulator Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America S1P Receptor Modulator Drugs Market Size (2018-2029)
6.2 North America S1P Receptor Modulator Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America S1P Receptor Modulator Drugs Market Size by Country (2018-2023)
6.4 North America S1P Receptor Modulator Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe S1P Receptor Modulator Drugs Market Size (2018-2029)
7.2 Europe S1P Receptor Modulator Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe S1P Receptor Modulator Drugs Market Size by Country (2018-2023)
7.4 Europe S1P Receptor Modulator Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific S1P Receptor Modulator Drugs Market Size (2018-2029)
8.2 Asia-Pacific S1P Receptor Modulator Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific S1P Receptor Modulator Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific S1P Receptor Modulator Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America S1P Receptor Modulator Drugs Market Size (2018-2029)
9.2 Latin America S1P Receptor Modulator Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America S1P Receptor Modulator Drugs Market Size by Country (2018-2023)
9.4 Latin America S1P Receptor Modulator Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa S1P Receptor Modulator Drugs Market Size (2018-2029)
10.2 Middle East & Africa S1P Receptor Modulator Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa S1P Receptor Modulator Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa S1P Receptor Modulator Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis International AG
11.1.1 Novartis International AG Company Detail
11.1.2 Novartis International AG Business Overview
11.1.3 Novartis International AG S1P Receptor Modulator Drugs Introduction
11.1.4 Novartis International AG Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.1.5 Novartis International AG Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb S1P Receptor Modulator Drugs Introduction
11.2.4 Bristol Myers Squibb Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Detail
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. S1P Receptor Modulator Drugs Introduction
11.3.4 Pfizer Inc. Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.3.5 Pfizer Inc. Recent Development
11.4 Sanofi SA
11.4.1 Sanofi SA Company Detail
11.4.2 Sanofi SA Business Overview
11.4.3 Sanofi SA S1P Receptor Modulator Drugs Introduction
11.4.4 Sanofi SA Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.4.5 Sanofi SA Recent Development
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Detail
11.5.2 Merck & Co., Inc. Business Overview
11.5.3 Merck & Co., Inc. S1P Receptor Modulator Drugs Introduction
11.5.4 Merck & Co., Inc. Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.5.5 Merck & Co., Inc. Recent Development
11.6 Biogen Inc.
11.6.1 Biogen Inc. Company Detail
11.6.2 Biogen Inc. Business Overview
11.6.3 Biogen Inc. S1P Receptor Modulator Drugs Introduction
11.6.4 Biogen Inc. Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.6.5 Biogen Inc. Recent Development
11.7 Roche Holding AG
11.7.1 Roche Holding AG Company Detail
11.7.2 Roche Holding AG Business Overview
11.7.3 Roche Holding AG S1P Receptor Modulator Drugs Introduction
11.7.4 Roche Holding AG Revenue in S1P Receptor Modulator Drugs Business (2018-2023)
11.7.5 Roche Holding AG Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details